Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Nuvation Bio Inc

NUVB ✗ NOT COMPLIANT ☆ Track — members

NYSE · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$6.22

▲ +1.97%

Market Cap $2.18B · Vol 1.96M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.18B

Mid Cap

Div Yield

N/A

EPS Growth

+38.54%

YoY

RSI (14)

41.54

Momentum

Beta

1.50

vs Market

52W High

$9.75

36.21% below

52W Low

$2.58

141.55% above

Volume

1.96M

Avg 1.61M

P/B

10.16

Price-to-book

ROE

-53.18%

Return on equity

Free Float

81.52%

Public shares

Shariah Compliance8 STANDARDS

✗ Nuvation Bio Inc (NUVB) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NUVB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.76%

+5.42%

+31.78%

+7.80%

YTD

-30.58%

+125.36%

+261.63%

-31.87%

Financials & Valuation

TTM · Annual

Total Revenue	$62.90M
Net Income	$-204,627,000.00
Revenue Growth (YoY)	+555.64%
Gross Margin	85.22%
Operating Margin	-338.72%
Net Profit Margin	-325.31%
ROE	-53.18%
ROA · ROIC	-36.04% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	48.65
P/B	10.16
P/FCF	N/A
EPS Growth	+38.54%
Outstanding Shares	351.12M

Technical Indicators

50-Day SMA	$5.88
200-Day SMA	$5.81
RSI (14)	41.54
Beta	1.50
52-Week High	$9.75
52-Week Low	$2.58

Volume Today	1.96M
Avg Daily Volume (30D)	1.61M
Relative Volume	1.21x
Volatility (10D)	60.84
Volatility (30D)	54.72
Free Float	81.52%

Analyst Consensus

BUY

Current Price $6.22

Mean Target $13.11

52W Low$2.58 52W High$9.75

Current

Target

$2.58 $9.75

Current Analyst target

+110.79% upside potential · 10 analysts

Identifiers

ExchangeNYSE

FIGIBBG00VHJ0CD0

ISINUS67080N1019

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Nuvation Bio Inc. is a global oncology company. The Company is focused on tackling cancer treatment. Its diverse pipeline includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor, and a drug-drug conjugate (DDC) program. IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor. Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), which is detected in various tumors, including gliomas. Its platform leverages its drug discovery and chemistry expertise to find the minimum target binding sites of drug X and drug Y and fuse them together, while maintaining activity. Its DDCs are designed to selectively bind to intracellular as well as surface cell membrane targets that are expressed more highly in specific target tissues and to potently deliver anti-cancer warheads to these target tissues.